Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Omics-characterization of tebufenpyrad effects on human primary hepatocytes

ABSTRACT: The biological effects of the pesticide and complex I inhibitor tebufenpyrad (TEBU) on liver cells were investigated by proteomic approaches. Cellular contents and culture media were analyzed in dose-response experiments on human primary hepatocytes (PHHs).

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, Cell Suspension Culture, Hepatocyte

SUBMITTER: Thibaut LEGER

LAB HEAD: Dr. Valerie Fessard

PROVIDER: PXD030887 | Pride | 2022-10-06

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	LT-DMSO-1.mgf	Mgf
	LT-DMSO-1.raw	Raw
	LT-DMSO-2.mgf	Mgf
	LT-DMSO-2.raw	Raw
	LT-DMSO-3.mgf	Mgf

Items per page:

1 - 5 of 29

Similar Datasets

Omics-characterization of tebufenpyrad effects on primary rat hepatocytes

Project description:The biological effects of the pesticide and complex I inhibitor tebufenpyrad (TEBU) on liver cells were investigated by proteomic approaches. Cellular contents and culture media were analyzed in dose-response experiments on primary rat hepatocytes (PRHs).

2022-10-06 | PXD030892 | Pride

Omics-characterization of tebufenpyrad effects on liver cells

Project description:The biological effects of the pesticide and complex I inhibitor tebufenpyrad (TEBU) on liver cells were investigated by proteomic approaches. Cellular contents were analyzed in dose-response experiments on differentiated HepaRG cell line. Moreover, kinetics were also investigated on HepaRG cells.

2022-10-06 | PXD030822 | Pride

Omics-characterization of tebufenpyrad effects on HepaRG : cell culture medium

Project description:The biological effects of the pesticide and complex I inhibitor tebufenpyrad (TEBU) on liver cells were investigated by proteomic approaches. Cell culture media were analyzed in dose-response experiments on differentiated HepaRG cell line. Moreover, kinetics were also investigated on HepaRG cells.

2022-10-06 | PXD031045 | Pride

First identification of ITM2B interactome in the human retina

Project description:ITM2B is a type II ubiquitous transmembrane protein which role remains unclear. ITM2B mutations have been associated with different disorders: mutations leading to longer mutant proteins have been reported in two distinct Alzheimer-like autosomal dominant disorders with early-onset progressive dementia, cerebellar ataxia, spasticity and variable degrees of deafness, early onset-cataract and vascular retinal abnormalities. Both disorders share neurological features including severe cerebral amyloid angiopathy, non-neuritic plaques, and fibrillary tangles as in Alzheimer Disease. Our group reported a missense mutation in ITM2B underlying an unusual retinal dystrophy with no dementia. This finding would suggest a specific role of ITM2B in the retina. The identification and characterization of retinal protein partners would bring new insights to the cellular functions of ITM2B in the retina. We performed ITM2B immunoprecipitation followed by quantitative proteomic analysis on normal human retina using two distinct antibodies recognizing different epitopes of the protein. Two pools of ITM2B protein partners were identified for each antibody and compared for functional annotation. Besides common proteins, specific partners involved in translation and mitochondrial homeostasis were identified suggesting a role of ITM2B in these cellular functions. To our knowledge, this is the first report of ITM2B interactome in human retina. Our findings also support a unique and specific role for the newly annotated ITM2B protein isoform.

2021-09-09 | PXD020088 | Pride

Pesticide and Insect Repellent Mixture (Permethrin and DEET) Induces Epigenetic Transgenerational Inheritance of Disease and Sperm Epimutations

Project description:Environmental compounds are known to promote epigenetic transgenerational inheritance of disease. The current study was designed to determine if a M-bM-^@M-^\pesticide mixtureM-bM-^@M-^] (pesticide permethrin and insect repellent N,N-Diethyl-meta-toluamide, DEET) promotes epigenetic transgenerational inheritance of disease and associated DNA methylation epimutations in sperm. Gestating F0 generation female rats were exposed during fetal gonadal sex determination and the incidence of disease evaluated in F1 and F3 generations. There were significant increases in the incidence of total diseases in animals from pesticide lineage F1 and F3 generation animals. Pubertal abnormalities, testis disease, and ovarian disease (primordial follicle loss and polycystic ovarian disease) were increased in F3 generation animals. Analysis of the pesticide lineage F3 generation sperm epigenome identified 363 differential DNA methylation regions (DMR) termed epimutations. Observations demonstrate that a pesticide mixture (permethrin and DEET) can promote epigenetic transgenerational inheritance of adult onset disease and potential sperm epigenetic biomarkers for ancestral environmental exposures. Methylated sperm DNA was isolated from rats ancestrally exposed to pesticides (Pip). Three independent samples from the treatment group were obtained. Differential DNA methylation between treatment groups was determined using Nimblegen microarrays. Treated samples were paired with control samples and hybridized together on arrays (Pip1/Cip1, Pip2/Cip2, and Pip3/Cip3), resulting in three arrays for the treatment.

2014-07-22 | E-GEOD-59554 | biostudies-arrayexpress

Transcription profiling of mouse IgE/antigen-activated mast cells stimulated with TIM-3

Project description:TIM-3 is known to be expressed on dendritic cells, monocytes, melanoma cells, mast cells and on activated Th1 cells. In activated Th1 cells, stimulating TIM-3 by one of its ligands, galectin-9, leads to apoptosis and thus it plays a central role in terminating Th1-type immune responses. Interestingly, in IgE/antigen-activated mast cells TIM-3 enhances the production of IL-13 and IL-4. To get a more complete picture about the gene expression changes induced by TIM-3 in mast cells, in vitro differentiated mouse immature mast cells were stimulated by an agonist anti-TIM-3 antibody and IgE-sensitized mouse immature mast cells were activated by antigen and an agonist anti-TIM-3 antibody for 2 or 16 hours (overnight). Experiment Overall Design: Bone marrow cells were differentiated in RPMI + 10% FCS + 5 ng/ml mouse IL-3 + 40 ng/ml mouse SCF for >4 weeks. The purity of the cell cultures was >90% at this time point (FcERIa+/c-kit+ cells). These in vitro-differentiated immature mast cells were then treated by either control goat IgG or an agonist anti-mouse TIM-3 antibody (RnD Systems, 15 ug/ml for 2 or 16 hours). For the IgE/antigen-activated mouse mast cells, these in vitro-differentiated immature mast cells were sensitized by 5 ug/ml anti-DNP IgE (Sigma) for 1 hour and then treated with 100 ng/ml DNP-HSA (antigen, Sigma) and either control goat IgG or an agonist anti-mouse TIM-3 antibody (RnD Systems, 15 ug/ml) for 2 or 16 hours. The anti-TIM-3 samples were labeled by Cy5 and they were compared to the Cy3-labeled, goat IgG controls in a dual-color, paired experimental setup. The Agilent Whole Mouse Genome 4x44K expression microarray kit and Dual-Color Protocol version 5.5 were used in the experiments.

2009-10-15 | E-GEOD-14438 | biostudies-arrayexpress

Methylation arrays (MethylationEPIC) of peripheral whole blood samples from adults aged between 19-96 years

Project description:Epigenetic remodeling is central to understanding the molecular mechanisms that occur and drive human aging. In fact, DNA methylation clocks are capable of estimating biological age, which determines human lifespan and healthspan. Here, using Illumina's MethylationEPIC array technology, we have profiled the DNA methylation landscape of peripheral whole blood samples from adult individuals ranging in age from 19 to 96 years.

2024-09-29 | E-MTAB-13431 | biostudies-arrayexpress

Novel antibody-peptide binding assay indicates presence of immunoglobulins against EGFR phospho-site S1166 in high-grade glioma.

Project description:The project’s aim was to develop and test the applicability of a method to determine the presence of serum immunoglobulins against specific autoantibodies. The method combined immunoglobulin G enrichment (using Melon Gel), molecular weight filtration, and targeted mass spectrometry and the feasibility was successfully tested in an experiment using a peptide library (tryptic digest) of dinitrophenyl labelled peptides and anti-DNP. In a second step, a phospho-peptide library, derived from glioblastoma multiform tissue, was tested against plasma samples from glioma patients and healthy donors, to determine the presence of complexes of IgG with immunoaffinity to EGFR or GFAP phospho-peptides. As a result, we found immunoaffinity to EGFR phospho-peptide GSHQIS[+80]LDNPDYQQDFFPK (covering the phospho-site S1166) in plasma of glioma patients.

2022-06-09 | PXD032844 | Pride

DNA methylation profiling of primary human dermal microvascular blood and lymphatic endothelial cells

Project description:Human dermal microvascular blood and lymphatic endothelial cells exhibit different DNA methylation patterns.

2021-01-18 | E-MTAB-8952 | biostudies-arrayexpress

Methylation arrays (MethylationEPIC) of cord and peripheral whole blood from children born to mothers with obesity or gestational diabetes, with longitudinal follow-up during their first year of life

Project description:Epidemiological studies have associated maternal metabolic conditions such as obesity and gestational diabetes with poor health outcomes in the offspring. Epigenetic mechanisms may help explain the intrauterine influence that mothers have on their offspring during pregnancy. Here, using Illumina's MethylationEPIC array technology, we have longitudinally profiled the blood methylomes of children born to mothers with obesity and obesity with gestational diabetes, and healthy controls, during the first year of life (measurements at 0, cord blood; 6 and 12 months, peripheral blood).

2023-03-01 | E-MTAB-12728 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data